4CPS-103 Second-generation tyrosin kinase inhibitors in front-line therapy. comparing responsesCM Valencia Soto, S Cortes-de Miguel, MV Villacañas-Palomares et al.|Section 4: Clinical pharmacy services|2018Cited by 0